IceCure Inks Exclusive Netherlands Distribution Deal as THERMAC Trial Advances to Phase III
ICCM sits 17% above its 52-week low of $2.12.
Summary
IceCure signed an exclusive distribution agreement with Scovas Medical for its ProSense cryoablation systems in the Netherlands, targeting breast cancer and interventional oncology. The deal supports European commercialization and leverages the Netherlands-based THERMAC trial, which has advanced to Phase III with cryoablation selected based on ProSense's 94% complete ablation rate, 0% complications, and 100% treatment tolerance. This follows the company's recent Nasdaq compliance resolution and H1 2026 revenue growth of 45%, though cash runway remains tight. The agreement is initial-term with potential for a longer-term extension, and the Phase III trial could provide further clinical validation in a key European market.
At the time of this announcement, ICCM was trading at $2.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $2.12 to $42.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.